In addition, it has been reported that the antitumor effect of β-elemene was also mediated by GMFβ-dependent inactivation of the ERK1/2-Bcl-2/survivin pathway, which suggests that β-elemene is a promising chemosensitizer for temozolomide against glioblastoma tumors [77]. The gene discussed is GMFB; the disease is glioblastoma.